

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>MINOGUE MICHAEL R</u> <hr/> (Last) (First) (Middle) C/O ABIOMED, INC., 22 CHERRY HILL DRIVE <hr/> (Street) DANVERS MA 01923 <hr/> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>ABIOMED INC [ABMD]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chairman, President, CEO		
			3. Date of Earliest Transaction (Month/Day/Year) 08/19/2020					
			4. If Amendment, Date of Original Filed (Month/Day/Year)					
			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock \$.01 par value	08/19/2020		G ⁽⁸⁾		20,883 ⁽⁸⁾	D	\$0	210,746	D	
Common Stock \$.01 par value	08/20/2020		M ⁽⁵⁾		60,000 ⁽⁵⁾	A	\$22.44	270,746	D	
Common Stock \$.01 par value	08/20/2020		S ⁽⁶⁾		3,759 ⁽⁶⁾	D	\$309.4 ⁽⁷⁾	266,987	D	
Common Stock \$.01 par value	08/20/2020		S ⁽⁶⁾		27,480 ⁽⁶⁾	D	\$310.09 ⁽⁷⁾	239,507	D	
Common Stock \$.01 par value	08/20/2020		S ⁽⁶⁾		14,196 ⁽⁶⁾	D	\$311.09 ⁽⁷⁾	225,311	D	
Common Stock \$.01 par value	08/20/2020		S ⁽⁶⁾		5,596 ⁽⁶⁾	D	\$312.08 ⁽⁷⁾	219,715	D	
Common Stock \$.01 par value	08/20/2020		S ⁽⁶⁾		6,254 ⁽⁶⁾	D	\$313.23 ⁽⁷⁾	213,461	D	
Common Stock \$.01 par value	08/20/2020		S ⁽⁶⁾		2,715 ⁽⁶⁾	D	\$314.13 ⁽⁷⁾	210,746	D	
Common Stock \$.01 par value	08/21/2020		M ⁽⁵⁾		40,000 ⁽⁵⁾	A	\$22.44	250,746	D	
Common Stock \$.01 par value	08/21/2020		S ⁽⁶⁾		14,600 ⁽⁶⁾	D	\$305.2 ⁽⁷⁾	236,146	D	
Common Stock \$.01 par value	08/21/2020		S ⁽⁶⁾		9,235 ⁽⁶⁾	D	\$306.11 ⁽⁷⁾	226,911	D	
Common Stock \$.01 par value	08/21/2020		S ⁽⁶⁾		11,189	D	\$307.24 ⁽⁷⁾	215,722	D	
Common Stock \$.01 par value	08/21/2020		S ⁽⁶⁾		4,876 ⁽⁶⁾	D	\$307.96 ⁽⁷⁾	210,846	D	
Common Stock \$.01 par value	08/21/2020		S ⁽⁶⁾		100 ⁽⁶⁾	D	\$310.1 ⁽⁷⁾	210,746	D	
Common Stock \$.01 par value	08/19/2020		G ⁽⁸⁾		20,883 ⁽⁸⁾	A	\$0	52,555	I	By Trust - A
Common Stock \$.01 par value								73,745	I	By Trust - B
Common Stock \$.01 par value								32,810	I	By Trust - C
Common Stock \$.01 par value								655	I	By Trust - D
Common Stock \$.01 par value								38,560	I	By Trust - E
Common Stock \$.01 par value								85,040	I	By Trust - F

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Option (Right to Buy) ⁽²⁾	\$22.44	08/20/2020		M ⁽⁵⁾		100,000 ⁽⁵⁾		05/22/2013 ⁽¹⁾	05/22/2022	Common Stock	\$0	0	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy) ⁽²⁾	\$23.15							05/14/2014 ⁽¹⁾	05/14/2023	Common stock	0		85,000	D	
Stock Option (right to buy) ⁽²⁾	\$21.55							05/14/2015 ⁽³⁾	05/14/2024	Common Stock	0		85,000	D	
Stock Option (right to buy) ⁽²⁾	\$66.25							05/13/2016 ⁽³⁾	05/13/2025	Common Stock	0		35,000	D	
Stock Option (right to buy) ⁽⁴⁾	\$99.62							05/24/2017 ⁽³⁾	05/24/2026	Common Stock	0		30,500	D	
Stock Option (right to buy) ⁽⁴⁾	\$134.51							05/15/2018 ⁽³⁾	05/15/2027	Common Stock	0		33,000	D	
Stock Option (right to buy) ⁽⁴⁾	\$381.97							05/16/2019 ⁽³⁾	05/16/2028	Common Stock	0		30,000	D	
Stock Option (right to buy) ⁽⁴⁾	\$266.39							05/30/2020 ⁽³⁾	05/30/2029	Common Stock	0		50,000	D	
Stock Option (Right to Buy) ⁽⁴⁾	\$223.9							05/29/2021 ⁽³⁾	05/29/2030	Common Stock	0		20,898	D	

Explanation of Responses:

- These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- Exercise of stock options pursuant to reporting owners 10b5-1 plan.
- Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$304.6400 and \$314.8000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust.

/s/ Ian W. McLeod (by power of attorney) 08/24/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

The undersigned does hereby appoint each of Stephen McEvoy, Ian McLeod, Michael Dube and Linda Day, signing singly, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director or officer of ABIOMED, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, this power of attorney has been executed as of the 2nd day of October, 2008 and shall remain in full force and effect until withdrawn by the undersigned in writing.

Signature: /s/ Michael R. Minogue

Print Name: Michael R. Minogue